2021 Revenues ($USD) : $9,101,957,393
2021 Revenues (foreign currencies) : JP¥999,759,000,000
2021 R&D spend : $1,181,718,864
2021 Number of Employees : 7,664
Fiscal Year End : 12/31/2021
Leader : CEO Osamu Okuda

Toko-based Chugai traces its origins back to 1925 with the founding of Chugai Shinyaku Co. Ltd., which began as a pharmaceutical importer. The company started its own drug production in 1927. In 2002, the company forged a strategic alliance with Roche that preserved Chugai’s autonomy while giving it the exclusive right to market Roche's products in Japan. Core drugs in its portfolios include Actemra (tocilizumab), an IL-6 signal blockade agent for rheumatoid arthritis and other autoimmune diseases, as well as Alecensa (alectinib), an ALK inhibitor for non-small cell lung cancer. Another key drug is Hemlibra (emicizumab-kxwh), an anti-factor IXa/X bispecific antibody for hemophilia A co-developed with Roche. —BB